Literature DB >> 32416059

Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal.

Rashim Pal Singh1, Danny V Jeyaraju1, Veronique Voisin2, Rose Hurren1, Changjiang Xu2, James R Hawley1, Samir H Barghout1, Dilshad H Khan1, Marcela Gronda1, Xiaoming Wang1, Yulia Jitkova1, David Sharon1, Sanduni Liyanagae1, Neil MacLean1, Ayesh K Seneviratene1, Sara Mirali1, Adina Borenstein1, Geethu E Thomas1, Joelle Soriano1, Elias Orouji1, Mark D Minden1, Andrea Arruda1, Steven M Chan1, Gary D Bader2, Mathieu Lupien1, Aaron D Schimmer3.   

Abstract

Leukemic stem cells (LSCs) rely on oxidative metabolism and are differentially sensitive to targeting mitochondrial pathways, which spares normal hematopoietic cells. A subset of mitochondrial proteins is folded in the intermembrane space via the mitochondrial intermembrane assembly (MIA) pathway. We found increased mRNA expression of MIA pathway substrates in acute myeloid leukemia (AML) stem cells. Therefore, we evaluated the effects of inhibiting this pathway in AML. Genetic and chemical inhibition of ALR reduces AML growth and viability, disrupts LSC self-renewal, and induces their differentiation. ALR inhibition preferentially decreases its substrate COX17, a mitochondrial copper chaperone, and knockdown of COX17 phenocopies ALR loss. Inhibiting ALR and COX17 increases mitochondrial copper levels which in turn inhibit S-adenosylhomocysteine hydrolase (SAHH) and lower levels of S-adenosylmethionine (SAM), DNA methylation, and chromatin accessibility to lower LSC viability. These results provide insight into mechanisms through which mitochondrial copper controls epigenetic status and viability of LSCs.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALR; AML; COX17; LSCs; copper

Mesh:

Substances:

Year:  2020        PMID: 32416059     DOI: 10.1016/j.stem.2020.04.010

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  9 in total

1.  Mitochondria regulate AML differentiation independent of oxidative phosphorylation and metabolism.

Authors:  Rashim Pal Singh; Aaron D Schimmer
Journal:  Mol Cell Oncol       Date:  2020-09-28

Review 2.  State-of-Art of Cellular Therapy for Acute Leukemia.

Authors:  Jong-Bok Lee; Daniel Vasic; Hyeonjeong Kang; Karen Kai-Lin Fang; Li Zhang
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

3.  Transduction of Primary AML Cells with Lentiviral Vector for In Vitro Study or In Vivo Engraftment.

Authors:  Aaron D Schimmer; Rashim Pal Singh; Ayesh K Seneviratne; Geethu E Thomas; Neil MacLean; Rose Hurren
Journal:  STAR Protoc       Date:  2020-11-25

4.  The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness.

Authors:  Geethu Emily Thomas; Grace Egan; Laura García-Prat; Aaron Botham; Veronique Voisin; Parasvi S Patel; Fieke W Hoff; Jordan Chin; Boaz Nachmias; Kerstin B Kaufmann; Dilshad H Khan; Rose Hurren; Xiaoming Wang; Marcela Gronda; Neil MacLean; Cristiana O'Brien; Rashim P Singh; Courtney L Jones; Shane M Harding; Brian Raught; Andrea Arruda; Mark D Minden; Gary D Bader; Razq Hakem; Steve Kornblau; John E Dick; Aaron D Schimmer
Journal:  Nat Cell Biol       Date:  2022-06-06       Impact factor: 28.213

5.  The core genes of cuproptosis assists in discerning prognostic and immunological traits of clear cell renal cell carcinoma.

Authors:  Binxiang Chu; Zhenghua Hong; Xiaohe Zheng
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

6.  Cuproptosis patterns and tumor microenvironment in endometrial cancer.

Authors:  Junfeng Chen; Guocheng Wang; Xiaomei Luo; Jing Zhang; Yongli Zhang
Journal:  Front Genet       Date:  2022-09-26       Impact factor: 4.772

7.  The role of mitochondrial proteases in leukemic cells and leukemic stem cells.

Authors:  Sara Mirali; Aaron D Schimmer
Journal:  Stem Cells Transl Med       Date:  2020-08-05       Impact factor: 6.940

Review 8.  Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia.

Authors:  Lucie de Beauchamp; Ekaterini Himonas; G Vignir Helgason
Journal:  Leukemia       Date:  2021-09-24       Impact factor: 11.528

9.  Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia.

Authors:  Margaret Am Nelson; Kelsey L McLaughlin; James T Hagen; Hannah S Coalson; Cameron Schmidt; Miki Kassai; Kimberly A Kew; Joseph M McClung; P Darrell Neufer; Patricia Brophy; Nasreen A Vohra; Darla Liles; Myles C Cabot; Kelsey H Fisher-Wellman
Journal:  Elife       Date:  2021-06-16       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.